Evidence map›Paper›PMID 25131735›Full record

Trial reportVaccine2014

Interaction between neonatal vitamin A supplementation and timing of measles vaccination: a retrospective analysis of three randomized trials from Guinea-Bissau.

Christine S Benn, Cesario L Martins, Ane B Fisker, Birgitte R Diness, May-Lill Garly, Ibraima Balde, Amabelia Rodrigues, Hilton Whittle, Peter Aaby

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Heterologous and sex differential effects of administering vitamin A supplementation with vaccines.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Christine S BennResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Artillerivej 5, 2300 Copenhagen S, Denmark; OPEN, Institute of Clinical Research, University of Southern Denmark/Odense University Hospital, Denmark. Electronic address: cb@ssi.dk.
Cesario L MartinsBandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
Ane B FiskerResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Artillerivej 5, 2300 Copenhagen S, Denmark.
Birgitte R DinessResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Artillerivej 5, 2300 Copenhagen S, Denmark.
May-Lill GarlyResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Artillerivej 5, 2300 Copenhagen S, Denmark.
Ibraima BaldeBandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
Amabelia RodriguesBandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
Hilton WhittleThe London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Peter AabyResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Artillerivej 5, 2300 Copenhagen S, Denmark; Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
Bandim Health Project · GWUniversity of London · GB

Funding

European Research Council 243149
6 · The paper itself

Abstract

backgroundIn Guinea-Bissau we conducted three trials of neonatal vitamin A supplementation (NVAS) from 2002 to 2008. None of the trials found a beneficial effect on mortality. From 2003 to 2007, an early measles vaccine (MV) trial was ongoing, randomizing children 1:2 to early MV at 4.5 months or no early MV, in addition to the usual MV at 9 months. We have previously found interactions between vitamin A and vaccines.

objectiveWe investigated whether there were interactions between NVAS and early MV.

designWe compared the mortality of NVAS and placebo recipients: first, from 4.5 to 8 months for children randomized to early MV or no early MV; and second, from 9 to 17 months in children who had received two MV or one MV. Mortality rates (MR) were compared in Cox models producing mortality rate ratios (MRR).

resultsA total of 5141 children were randomized to NVAS (N=3015) or placebo (N=2126) and were later randomized to early MV (N=1700) or no early MV (N=3441). Between 4.5 and 8 months, NVAS compared with placebo was associated with higher mortality in early MV recipients (MR=30 versus MR=0, p=0.01), but not in children who did not receive early MV (p for interaction between NVAS and early MV=0.03). From 9 to 17 months NVAS was not associated with mortality. Overall, from 4.5 to 17 months NVAS was associated with increased mortality in early MV recipients (Mortality rate ratio=5.39 (95% confidence interval: 1.62, 17.99)).

conclusionsThese observations indicate that NVAS may interact with vaccines given several months later. This may have implications for the planning of future child intervention programs.

Indexed as

Dietary SupplementsImmunization ScheduleMortalityFemaleGuinea-BissauHumansImmunization, SecondaryInfantMaleMeaslesMeasles VaccineProportional Hazards ModelsRetrospective StudiesVaccinationVitamin AMeasles VaccineVitamin AChildrenLow-income countriesMeasles vaccineMortalityVitamin A

Identifiers

PMID25131735
PMCPMC4180001
OpenAlexW2055735546

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.